Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
1989-7-20
|
| pubmed:abstractText |
The toxicity and therapeutic efficacy of the combination of recombinant interferon gamma (rIFN-gamma) and alpha (rIFN-alpha) was investigated in 15 patients with metastatic melanoma. Patients were treated with an escalating dose of rIFN-gamma and a fixed dose of rIFN-alpha administered s.c. 3 times a week. The maximum dose was well tolerated. The median survival time of the patients was 7 months; no clinical remissions were observed. In the majority of cases, expression of HLA class-I and -II antigens on the patients' peripheral blood lymphocytes and monocytes increased markedly during treatment. An increase in HLA-DR expression of peripheral blood T lymphocytes was correlated with a longer survival time. This suggests that activation of T lymphocytes may have a favourable influence on the course of metastatic disease. The in vitro anti-proliferative activity of IFNs on melanoma cell lines isolated from melanoma metastases during treatment of 3 patients was determined. In contrast to the lack of in vivo anti-tumour effect in patients, both rIFN-gamma and rIFN-alpha inhibited DNA synthesis of these melanoma cell lines in vitro, combined IFNs acting synergistically. Anti-proliferative activity observed in vitro occurred at IFN concentrations below the peak serum levels achieved in vivo.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0020-7136
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
43
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1001-6
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2499552-Cell Division,
pubmed-meshheading:2499552-Cell Separation,
pubmed-meshheading:2499552-Clinical Trials as Topic,
pubmed-meshheading:2499552-Dose-Response Relationship, Drug,
pubmed-meshheading:2499552-Drug Synergism,
pubmed-meshheading:2499552-Drug Therapy, Combination,
pubmed-meshheading:2499552-Flow Cytometry,
pubmed-meshheading:2499552-Histocompatibility Antigens Class I,
pubmed-meshheading:2499552-Histocompatibility Antigens Class II,
pubmed-meshheading:2499552-Humans,
pubmed-meshheading:2499552-Injections, Subcutaneous,
pubmed-meshheading:2499552-Interferon Type I,
pubmed-meshheading:2499552-Interferon-gamma,
pubmed-meshheading:2499552-Leukocytes, Mononuclear,
pubmed-meshheading:2499552-Melanoma,
pubmed-meshheading:2499552-Neoplasm Metastasis,
pubmed-meshheading:2499552-Recombinant Proteins,
pubmed-meshheading:2499552-Time Factors,
pubmed-meshheading:2499552-Tumor Cells, Cultured
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma.
|
| pubmed:affiliation |
Department of Clinical Oncology, University Hospital, Leiden, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|